PE20191320A1 - Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus - Google Patents
Constructos de vacuna y sus usos contra infecciones causadas por staphylococcusInfo
- Publication number
- PE20191320A1 PE20191320A1 PE2019000844A PE2019000844A PE20191320A1 PE 20191320 A1 PE20191320 A1 PE 20191320A1 PE 2019000844 A PE2019000844 A PE 2019000844A PE 2019000844 A PE2019000844 A PE 2019000844A PE 20191320 A1 PE20191320 A1 PE 20191320A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- polypeptide
- amino acid
- construct
- absent
- Prior art date
Links
- 208000015181 infectious disease Diseases 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 241000191940 Staphylococcus Species 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 11
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 11
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 11
- 241000191967 Staphylococcus aureus Species 0.000 abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 101100227953 Staphylococcus aureus (strain COL) fur gene Proteins 0.000 abstract 1
- 101100404789 Staphylococcus aureus (strain COL) nikC gene Proteins 0.000 abstract 1
- 101100422138 Staphylococcus aureus (strain COL) splC gene Proteins 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
Referido a un constructo de fusion de formula (I): XA-ligante-BZ (I); en donde A y B son, independientemente, un polipeptido que comprende un polipeptido SACOL0029 (SEQ ID NO: 5 y 121 a 131), un polipeptido SACOL0264 (SEQ ID NO: 185), un polipeptido SACOL0442 (SEQ ID NO: 29 y 82 a 92), un polipeptido SACOL0718 (SEQ ID NO: 186), un polipeptido SACOL0720 (SEQ ID NO: 11 y 109 a 120), un polipeptido SACOL1353 (SEQ ID NO: 187), un polipeptido SACOL1416 (SEQ ID NO: 188), un polipeptido SACOL1611 (SEQ ID NO: 189), un SACOL1867 (SEQ ID NO: 152 a 164), un polipeptido SACOL1912 (SEQ ID NO: 43), un polipeptido SACOL1944 (SEQ ID NO: 190), entre otros, sobre la base de la nomenclatura genetica del genoma COL (SACOL) de Staphylococcus aureus expuesto en la Secuencia de Referencia de NCBI NC_002951.2; el ligante es una secuencia de aminoacidos de por lo menos un aminoacido o esta ausente; X esta ausente o es una secuencia de aminoacidos; y Z esta ausente o es una secuencia de aminoacidos. Dicho constructo exhibe una mayor inmunogenicidad, siendo util como vacuna contra la infeccion intramamaria estafilococica (IIM) causada por Staphylococcus aureus. Tambien se refiere a una molecula de acido nucleico que codifica dicho constructo, un vector, una celula huesped que es una forma viva de Staphylococcus aureus y una composicion farmaceutica que comprende dicho constructo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662411120P | 2016-10-21 | 2016-10-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20191320A1 true PE20191320A1 (es) | 2019-09-24 |
Family
ID=62018642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019000844A PE20191320A1 (es) | 2016-10-21 | 2017-10-20 | Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US11324815B2 (es) |
| EP (1) | EP3529260A4 (es) |
| JP (2) | JP7181208B2 (es) |
| KR (1) | KR20190082229A (es) |
| CN (1) | CN109843910A (es) |
| AR (1) | AR109847A1 (es) |
| AU (2) | AU2017346974B2 (es) |
| BR (1) | BR112019007796A2 (es) |
| CA (1) | CA3037070A1 (es) |
| CL (1) | CL2019001048A1 (es) |
| CO (1) | CO2019005169A2 (es) |
| CR (1) | CR20190249A (es) |
| DO (1) | DOP2019000102A (es) |
| IL (1) | IL265869A (es) |
| MX (2) | MX2019004539A (es) |
| MY (1) | MY195369A (es) |
| NZ (1) | NZ751880A (es) |
| PE (1) | PE20191320A1 (es) |
| PH (1) | PH12019500843A1 (es) |
| RU (2) | RU2766354C2 (es) |
| SG (2) | SG10201912431XA (es) |
| TW (1) | TW201819402A (es) |
| UY (1) | UY37448A (es) |
| WO (1) | WO2018072031A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113777317A (zh) * | 2020-06-09 | 2021-12-10 | 首都医科大学附属北京世纪坛医院 | 尿液主穹隆蛋白及其多肽片段在烧伤中的应用 |
| WO2022125928A1 (en) * | 2020-12-11 | 2022-06-16 | Bayer Animal Health Gmbh | Methods and compositions for improved production of an antigen for use in an s. aureus vaccine |
| US12161970B1 (en) | 2024-08-09 | 2024-12-10 | Jiaxing Research Institute, Zhejiang University | CO2 desorption system suitable for limited space in complex sailing region and flexible control method |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA8681B (en) | 1985-01-07 | 1987-08-26 | Syntex Inc | 1,2-dialkoxy-omega-trialkylammonium cationic surfactants |
| US6228844B1 (en) | 1991-11-12 | 2001-05-08 | Vical Incorporated | Stimulating vascular growth by administration of DNA sequences encoding VEGF |
| US7060458B1 (en) | 1997-08-14 | 2006-06-13 | Wyeth | Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics |
| US6380370B1 (en) * | 1997-08-14 | 2002-04-30 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics |
| US6833134B2 (en) | 2000-06-12 | 2004-12-21 | University Of Saskacthewan | Immunization of dairy cattle with GapC protein against Streptococcus infection |
| GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
| CN100351260C (zh) | 2002-11-12 | 2007-11-28 | 布赖汉姆妇女医院 | 葡萄球菌感染的多糖疫苗 |
| CN1569893A (zh) | 2003-07-21 | 2005-01-26 | 中国人民解放军军事医学科学院基础医学研究所 | 金葡菌毒力因子调控蛋白的抗原表位及其模拟表位和用途 |
| RU2419628C2 (ru) | 2004-09-22 | 2011-05-27 | ГлаксоСмитКлайн Байолоджикалз с.а. | Иммуногенная композиция для применения в вакцинации против стафилококков |
| EP2340848A3 (en) * | 2004-10-21 | 2011-09-14 | Wyeth LLC | Immunogenic compositions of Staphylococcus epidermidis polypeptide and polynucleotide antigens |
| WO2006059846A1 (en) | 2004-12-01 | 2006-06-08 | Lg Life Sciences, Ltd. | Formulation of sec1 mutated protein and method for formulation of the same |
| CA2667788A1 (en) | 2006-10-30 | 2008-12-18 | The University Of Western Ontario | Staphylococcus aureus specific anti-infectives |
| JP2012521441A (ja) | 2009-03-23 | 2012-09-13 | エピトピックス，リミティド ライアビリティ カンパニー | ポリペプチド及びグラム陽性ポリペプチドを含有する免疫化組成物並びにこれらの使用方法 |
| WO2010119343A2 (en) | 2009-04-14 | 2010-10-21 | Novartis Ag | Compositions for immunising against staphylococcus aureus |
| SI2547361T1 (sl) | 2010-03-17 | 2021-01-29 | SOCPRA - Sceiences et Genie, s.e.c. | Bakterijske komponente cepiva iz staphylococcus aureus in njihova uporaba |
| CN104474531A (zh) | 2011-06-19 | 2015-04-01 | 纽约大学 | 治疗和预防金黄色葡萄球菌感染及相关病状的方法 |
-
2017
- 2017-10-20 JP JP2019542759A patent/JP7181208B2/ja active Active
- 2017-10-20 BR BR112019007796A patent/BR112019007796A2/pt not_active IP Right Cessation
- 2017-10-20 SG SG10201912431XA patent/SG10201912431XA/en unknown
- 2017-10-20 AR ARP170102922A patent/AR109847A1/es not_active Application Discontinuation
- 2017-10-20 TW TW106136089A patent/TW201819402A/zh unknown
- 2017-10-20 NZ NZ751880A patent/NZ751880A/en unknown
- 2017-10-20 AU AU2017346974A patent/AU2017346974B2/en not_active Ceased
- 2017-10-20 EP EP17863203.0A patent/EP3529260A4/en active Pending
- 2017-10-20 MY MYPI2019002159A patent/MY195369A/en unknown
- 2017-10-20 RU RU2019115303A patent/RU2766354C2/ru active
- 2017-10-20 RU RU2022100889A patent/RU2022100889A/ru unknown
- 2017-10-20 UY UY0001037448A patent/UY37448A/es unknown
- 2017-10-20 PE PE2019000844A patent/PE20191320A1/es unknown
- 2017-10-20 CN CN201780064991.1A patent/CN109843910A/zh active Pending
- 2017-10-20 US US16/337,457 patent/US11324815B2/en active Active
- 2017-10-20 CR CR20190249A patent/CR20190249A/es unknown
- 2017-10-20 CA CA3037070A patent/CA3037070A1/en active Pending
- 2017-10-20 KR KR1020197014191A patent/KR20190082229A/ko not_active Abandoned
- 2017-10-20 MX MX2019004539A patent/MX2019004539A/es unknown
- 2017-10-20 WO PCT/CA2017/051253 patent/WO2018072031A1/en not_active Ceased
- 2017-10-20 SG SG11201901483QA patent/SG11201901483QA/en unknown
-
2019
- 2019-04-07 IL IL265869A patent/IL265869A/en unknown
- 2019-04-16 PH PH12019500843A patent/PH12019500843A1/en unknown
- 2019-04-17 MX MX2023001219A patent/MX2023001219A/es unknown
- 2019-04-17 DO DO2019000102A patent/DOP2019000102A/es unknown
- 2019-04-17 CL CL2019001048A patent/CL2019001048A1/es unknown
- 2019-05-21 CO CONC2019/0005169A patent/CO2019005169A2/es unknown
-
2022
- 2022-04-05 US US17/713,683 patent/US20220288183A1/en not_active Abandoned
- 2022-06-28 AU AU2022204585A patent/AU2022204585A1/en not_active Abandoned
- 2022-11-16 JP JP2022183528A patent/JP2023025066A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018002825A1 (es) | Vacuna contra vrs | |
| CY1123189T1 (el) | Αντιμικροβiακο πεπτιδιο | |
| ES2688623T3 (es) | Proteínas de fusión que se unen a factores de crecimiento | |
| ES2722799T3 (es) | Vacunas contra el cáncer de cerebro basadas en el péptido alfa 2 del receptor de interleuquina-13 | |
| CY1118331T1 (el) | Χιμαιρικα πολυπεπτιδια και η χρηση τους στην εκριζωση φορειας βακτηριων | |
| PE20191320A1 (es) | Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus | |
| GB201206559D0 (en) | Polypeptide | |
| CU24570B1 (es) | Proteínas de bacillus thuringiensis quiméricas insecticidas tóxicas o inhibidoras de plagas de lepidópteros | |
| PE20090483A1 (es) | Vectores para la expresion multiple de genes | |
| PE20140986A1 (es) | Proteinas de fusion y vacunas de combinacion que comprenden proteina e y pilina a de haemophilus influenzae | |
| ECSP10010637A (es) | Anticuerpos anti-factor d humanizados y sus usos | |
| MX2019005269A (es) | Formulaciones estables de dominios variables sencillos de inmunoglobulina y usos de las mismas. | |
| UA116431C2 (uk) | Композиція для попередження інфекції mycoplasma spp. | |
| CO6731074A2 (es) | Composición vacunal para el control de las infestaciones por ectoparásitos | |
| MX2016006277A (es) | Secuencia de endolisina kz144 modificada. | |
| MX392412B (es) | Polipéptidos que tienen actividad inductora de inmunidad. | |
| MX2018001200A (es) | Nuevos microorganismos y su uso en la agricultura. | |
| MX348934B (es) | Secuencias de aminoacidos para el control de patogenos. | |
| BR102013026625A8 (pt) | vacina de peptídeos recombinantes para o controle de carrapatos e sequências de nucleotídeos codificadoras dos peptídeos recombinantes | |
| CO6690750A2 (es) | Compuestos de ditiínatetra (tio) carboximidas y procedimientos para la preparación de estos compuestos | |
| UA112297C2 (uk) | Рекомбінантна мікобактерія як вакцина для застосування на людях | |
| PL405911A1 (pl) | Białko o aktywności hydrolitycznej wobec polisacharydowych otoczek bakteryjnych, polinukleotyd kodujący to białko, biologicznie czynny wektor, kompozycja zawierająca białko i jego zastosowanie | |
| MX2020001046A (es) | Composicion inmunogenica que comprende un peptido de fusion derivado de toxoides de superantigenos. | |
| AR056782A1 (es) | Uso de polinucleotidos armadillo repeat (arm1) para lograr una resitencia contra agentes patogenos en plantas | |
| AR079370A1 (es) | Uso de peptidos antimicrobianos para el tratamiento de infeccion urinaria/cistitis |